Astellas, Medivation initiate TRUMPET registry study

Many patients newly diagnosed with castration-resistant prostate cancer (CRPC) may be interested in participating in a new registry study known as the TRUMPET study, which has just started to enroll patients and is sponsored by Astellas and Medivation (the developers and marketers of enzalutamide/Xtandi). … READ MORE …

US national prostate cancer registry coming to life soon

At the annual meeting of the American Urological Association (AUA) this morning, Dr. Matt Cooperberg reported that a total of 450 US-based urologists had now signed up to contribute data on their prostate cancer patients to the AQUA Registry. … READ MORE …

Patterns of treatment of European patients with CRPC in 2009-10

The full text of an article by Sternberg et al. (originally published in BMC Urology in 2013) has just been published to the Medscape Oncology web site and addresses patterns of treatment of men with castration-resistant prostate cancer (CRPC) in five European nations before wide availability of abiraterone. … READ MORE …

PSA levels, prostate cancer risk, and diagnosis in the “real world”

For all of the academic literature and the recommendations of guideline-generating organizations on testing, diagnosis, and management of prostate cancer, urologists out in community practice may show considerable variation in their clinical practice patterns. … READ MORE …